Skip to main content

Table 3 Univariate and multivariate analyses of prognostic factors including serum E2 level for metastasis-free survival according to ER status

From: Prognostic effect of preoperative serum estradiol level in postmenopausal breast cancer

  ER positive group ER negative group
  Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
  HR 95% CI p value HR 95% CI p value HR 95% CI p value HR 95% CI p value
Age 1.06 0.97-1.16 0.24     1.02 0.95-1.09 0.63    
BMI, ≥23 kg/m2 1.22 0.52-2.86 0.64     1.02 0.37-2.82 0.97    
HER2/neu positive 0.99 0.98-1.01 0.69     0.97 0.33-2.84 0.96    
Tumor size, >2 cm 10.65 1.28-88.48 0.03 3.75 0.41-33.98 0.24 4.75 1.07-21.06 0.04 1.85 0.37-9.27 0.45
Node metastasis             
0 Ref.    Ref.    Ref.      
1-3 1.47 0.13-16.25 0.75 1.12 0.10-12.66 0.93 4.00 1.17-13.70 0.03 2.45 0.65-9.31 0.19
>3 18.96 3.47-103.63 0.001 9.05 1.50-54.45 0.02 10.70 2.67-42.90 0.001 2.99 0.62-14.36 0.17
Nuclear grade 3 3.06 1.06-8.83 0.04 1.21 0.08-19.62 0.87 1.11 0.53-2.34 0.78    
Histologic grade 3 3.59 1.24-10.38 0.02 8.04 0.54-120.81 0.13 1.16 0.55-2.45 0.69    
ELTE 2.91 0.65-13.00 0.16     8.28 2.63-26.06 <0.001 4.24 1.18-15.18 0.03
E2 level, >13 pg/ml 2.54 0.49-13.13 0.27     3.373 1.07-10.61 0.04 3.32 1.05-10.51 0.04
Chemotherapy 2.49 0.92-6.75 0.07          
  1. A multivariate analysis was set by using all of the predictors with p values under 0.05 in univariate analysis.
  2. Abbreviations: ER estrogen receptor, BMI Body mass index, ELTE endolymphatic tumor emboli, E2 Estradiol.